Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
$JNJ A legal storm just scored a direct hit, yet this healthcare giant refuses to fall. Johnson & Johnson absorbed a blow after a Texas bankruptcy court rejected its structured settlement plan for talc lawsuits. The stock, trading at $225.33, held firm above its critical 200-day moving average of $211.62. This resilience points to a safe harbor, not a sinking ship.
🔹 Temporary legal fog cannot silence a roaring operational engine. The revenue loss from patent expirations on drugs like Stelara is being rapidly offset by powerful growth in the oncology segment. This portfolio transformation is so strong that the consensus earnings estimate for 2026 has been raised to $11.57 per share. The company is not simply shrinking; it is restructuring profitably.
🔹 The technical picture shows the scars of a short-term storm, but the defensive line holds. With a market capitalization of $542.4 billion and a dividend yield of 2.38%, JNJ remains a shelter for funds fleeing technology-driven volatility. The recent selling pressure is a healthy breather, not a panic.
A giant clearing a legal hurdle, closing a patent cliff with oncology strength, and sustaining a reliable cash flow stream. Do you keep this kind of defensive insurance in your portfolio?
⚠️ Not financial advice.
👉 DYOR ☑️
🔹 Temporary legal fog cannot silence a roaring operational engine. The revenue loss from patent expirations on drugs like Stelara is being rapidly offset by powerful growth in the oncology segment. This portfolio transformation is so strong that the consensus earnings estimate for 2026 has been raised to $11.57 per share. The company is not simply shrinking; it is restructuring profitably.
🔹 The technical picture shows the scars of a short-term storm, but the defensive line holds. With a market capitalization of $542.4 billion and a dividend yield of 2.38%, JNJ remains a shelter for funds fleeing technology-driven volatility. The recent selling pressure is a healthy breather, not a panic.
A giant clearing a legal hurdle, closing a patent cliff with oncology strength, and sustaining a reliable cash flow stream. Do you keep this kind of defensive insurance in your portfolio?
⚠️ Not financial advice.
👉 DYOR ☑️